Drug Patent Watch

JULY 26, 2022

This chart shows the generic pharmaceutical companies that had the most successful drug patent challenges from 2017 to 2022. Companies that successfully challenge patents on branded drugs are granted six…. The post Most prolific drug patent challengers appeared first on DrugPatentWatch - Make Better Decisions.

Generic Pharmaceutical 85

Generic Pharmaceutical Drugs Branding 85

Drug Patent Watch

JULY 26, 2021

This chart shows the generic pharmaceutical companies that had the most successful drug patent challenges from 2016 to 2021. Companies that successfully challenge patents on branded drugs are granted six…. The post Most prolific drug patent challengers appeared first on DrugPatentWatch - Make Better Decisions.

Generic Pharmaceutical 98

Generic Pharmaceutical Drugs Branding 98

Drug Patent Watch

NOVEMBER 9, 2021

This chart shows the generic pharmaceutical companies that had the most successful drug patent challenges from 2016 to 2021. Companies that successfully challenge patents on branded drugs are granted six…. The post Most prolific drug patent challengers appeared first on DrugPatentWatch - Make Better Decisions.

Generic Pharmaceutical 89

Generic Pharmaceutical Drugs Branding 89

Drug Patent Watch

JULY 26, 2023

This chart shows the generic pharmaceutical companies that had the most successful drug patent challenges from 2018 to 2023. Companies that successfully challenge patents on branded drugs are granted six… The post Most prolific drug patent challengers appeared first on DrugPatentWatch - Make Better Decisions.

Generic Pharmaceutical 52

Generic Pharmaceutical Drugs Branding 52

Drug Patent Watch

NOVEMBER 9, 2022

This chart shows the generic pharmaceutical companies that had the most successful drug patent challenges from 2017 to 2022. Companies that successfully challenge patents on branded drugs are granted six…. The post Most prolific drug patent challengers appeared first on DrugPatentWatch - Make Better Decisions.

Generic Pharmaceutical 52

Generic Pharmaceutical Drugs Branding 52

Pharmaceutical Technology

JUNE 1, 2023

Dipharma is a pioneer in developing improved generic pharmaceutical products for rare diseases: our desire to innovate and our engagement do not stop, but every day we continue to seek new and better solutions for patients around the world.”

FDA Approval 130

FDA Approval Generic Pharmaceutical Drugs Production 130

Pharmaceutical Technology

FEBRUARY 28, 2023

Novartis overview Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products.

Generic Pharmaceutical 172

Generic Pharmaceutical Dermatology Clinical Trials Clinical Trials 172

BioTech 365

AUGUST 4, 2021

the “Company”) (OTC PINK:SHMN), a generic Pharmaceutical, Nutraceutical, and Cosmeceutical company that manufactures and markets generic … Continue reading → Chino Hills, 08/04/2021 / 15:52, CET/CEST – EQS Newswire – Sohm, Inc. CHINO HILLS, CA / ACCESSWIRE / August 4, 2021 / SOHM, Inc.

Manufacturing 40

Manufacturing Generic Pharmaceutical Production Development 40

BioTech 365

MAY 18, 2021

OTC PINK:SHMN), a generic pharmaceutical, nutraceutical, and cosmeceutical company that manufactures and markets generic drugs covering … Continue reading → Chino Hills, 05/18/2021 / 15:31, CET/CEST – EQS Newswire – Sohm, Inc. CHINO HILLS, CA / ACCESSWIRE / May 18, 2021 / SOHM, Inc.

Generic Pharmaceutical 40

Generic Pharmaceutical Generic Drugs Manufacturing Marketing 40

BioTech 365

JUNE 3, 2021

the “Company”) (OTC PINK:SHMN), generic Pharmaceutical, Nutraceutical, and Cosmeceutical company that manufactures and markets generic drugs … Continue reading → Chino Hills, 06/03/2021 / 18:51, CET/CEST – EQS Newswire – Sohm, Inc. CHINO HILLS, CA / ACCESSWIRE / June 3, 2021 / SOHM, Inc.

Generic Pharmaceutical 40

Generic Pharmaceutical Generic Drugs Manufacturing Marketing 40

Pharmaceutical Technology

FEBRUARY 28, 2023

Novartis overview Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products.

Generic Pharmaceutical 100

Generic Pharmaceutical Dermatology Clinical Trials Clinical Trials 100

BioTech 365

MAY 13, 2021

First Nation Group Announces Launch of Pharmaceuticals Division First Nation Group Announces Launch of Pharmaceuticals Division First Nation Group launches new division, First Nation Pharmaceuticals, offering generic pharmaceutical distribution and supply chain management NICEVILLE, Fla.–(BUSINESS

Generic Pharmaceutical 52

Generic Pharmaceutical 52

BioTech 365

DECEMBER 31, 2020

NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced its financial results for the … Continue reading → Announces Third Quarter 2020 Results Teligent, Inc. Announces Third Quarter 2020 Results BUENA, N.J., 31, 2020 (GLOBE NEWSWIRE) — Teligent, Inc.

Generic Pharmaceutical 40

Generic Pharmaceutical 40

BioTech 365

MARCH 12, 2021

Amring Pharmaceuticals Inc. –(BUSINESS WIRE)–Amring Pharmaceuticals Inc. Amring), a niche brand and generic pharmaceutical company, announced today an … Continue reading → Enters into License and Development Agreement with Amzell B.V. BERWYN, Pa.–(BUSINESS

Licensing 52

Licensing Licensing Generic Pharmaceutical Development 52

Drug Patent Watch

NOVEMBER 8, 2020

This chart shows the generic pharmaceutical companies that had the most successful drug patent challenges from 2015 to 2020. Companies that successfully challenge patents on branded drugs are granted six…. The post Most prolific drug patent challengers appeared first on DrugPatentWatch - Make Better Decisions.

Generic Pharmaceutical 40

Generic Pharmaceutical Drugs Branding 40

BioTech 365

DECEMBER 2, 2020

Amring Pharmaceuticals Inc. Acquires LYSTEDA® Amring Pharmaceuticals Inc. –(BUSINESS WIRE)–Amring Pharmaceuticals Inc. Amring), a generic pharmaceutical company, announced entering into an agreement with Ferring International Center S.A. Acquires LYSTEDA® BERWYN, Pa.–(BUSINESS

Generic Pharmaceutical 52

Generic Pharmaceutical 52

Pharmaceutical Technology

JULY 28, 2022

The current standards of care (SOCs) in OA focus on symptom management and are made up of generic pharmaceuticals, including nonsteroidal anti-inflammatory drugs (NSAIDs), opioids, antidepressants and intra-articular (IA) injections. There are no disease-modifying drugs currently approved for OA.

Marketing 130

Marketing Generic Pharmaceutical Sales Production 130

BioTech 365

SEPTEMBER 23, 2020

NASDAQ: TLGT) (“Teligent” or the “Company”), a New Jersey-based specialty generic pharmaceutical company, announced the closing of the issuance of approximately $27.5 BUENA, N.J., 23, 2020 (GLOBE NEWSWIRE) — Teligent, Inc.

Generic Pharmaceutical 40

Generic Pharmaceutical 40

Pharmaceutical Technology

FEBRUARY 28, 2023

Novartis overview Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It was also under development for the treatment of idiopathic/primary membranous nephropathy.

Generic Pharmaceutical 100

Generic Pharmaceutical Dermatology Drugs Clinical Trials 100

Pharmaceutical Technology

FEBRUARY 28, 2023

Novartis overview Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It was also under development for the treatment of idiopathic/primary membranous nephropathy.

Generic Pharmaceutical 100

Generic Pharmaceutical Dermatology Drugs Clinical Trials 100

Drug Channels

SEPTEMBER 10, 2020

Today’s guest post comes from George Keefe, Senior Vice President of External Affairs and Public Policy at Teva Pharmaceuticals. George examines the economic impact of generic pharmaceuticals on the U.S. He argues that the generics industry provides safe, effective, and affordable medicines for many Americans.

Medicine 52

Medicine Generic Pharmaceutical Drugs 52

XTalks

DECEMBER 14, 2020

AvKARE, a generics pharmaceutical manufacturer based in Pulaski, Tennessee, has issued a recall on one lot each of its sildenafil 100 mg tablets and trazodone 100 mg tablets due to a packaging “mix-up” in which both drugs were filled into the same bottle. According to AvKARE, the error occurred at a third-party bottle filling facility.

Packaging 93

Packaging Packaging Drugs Generic Pharmaceutical 93

Pharmaceutical Technology

SEPTEMBER 22, 2022

The current standards of care (SOCs) in OA focus on symptom management and are made up of generic pharmaceuticals, including nonsteroidal anti-inflammatory drugs (NSAIDs), opioids, antidepressants, and intra-articular injections.

Marketing 147

Marketing Generic Pharmaceutical Clinical Trials Clinical Trials 147

Pharmaceutical Technology

FEBRUARY 18, 2023

Novartis Overview Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It was under development for renal cell carcinoma as first line therapy.

Generic Pharmaceutical 100

Generic Pharmaceutical Dermatology Antibody Development 100

The Pharma Data

JANUARY 4, 2021

Meiji Seika Pharma, since it launched penicillin in Japan in 1946, has been providing high-quality pharmaceutical products such as antibiotics, antidepressants and antipsychotics in Japan and overseas. Integrated Reports: [link].

Generic Pharmaceutical 40

Generic Pharmaceutical Generic Drugs Clinical Development Clinical Research 40

XTalks

DECEMBER 14, 2020

AvKARE, a generics pharmaceutical manufacturer based in Pulaski, Tennessee, has issued a recall on one lot each of its sildenafil 100 mg tablets and trazodone 100 mg tablets due to a packaging “mix-up” in which both drugs were filled into the same bottle. According to AvKARE, the error occurred at a third-party bottle filling facility.

Packaging 52

Packaging Packaging Drugs Generic Pharmaceutical 52

The Pharma Data

JUNE 17, 2022

About Sandoz Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. Our ambition is to be the world’s leading and most valued generics company. The adalimumab reference medicine (Humira ®* ) was first approved with an adalimumab concentration of 50 mg/mL.

Medicine 52

Medicine Generic Pharmaceutical FDA Approval Packaging 52

The Pharma Data

APRIL 4, 2023

About Sandoz Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. Our ambition is to be the world’s leading and most valued generics company. The adalimumab reference medicine (Humira ® *) was first approved with an adalimumab concentration of 50 mg/mL.

Medicine 40

Medicine Generic Pharmaceutical FDA Approval Marketing 40

XTalks

JUNE 8, 2022

Sandoz is a pioneering leader in generic pharmaceuticals and biosimilars, as Sandoz launched the world’s first biosimilar in Europe in 2006 and won the first biosimilar approval in the US in 2014. Related: Cyltezo Becomes First FDA-Approved Interchangeable Humira Biosimilar.

Generic Pharmaceutical 69

Generic Pharmaceutical Production Medicine Branding 69

Pharmaceutical Technology

SEPTEMBER 23, 2022

They have launched multiple OTC and Rx generic pharmaceuticals into the US and have also supported several international markets. Avéma Pharma Solutions and PL Developments bring decades of product development and commercialisation experience to the table.

Manufacturing 147

Manufacturing Drugs Production Development 147

The Pharma Data

MAY 31, 2022

About Sandoz Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. Our ambition is to be the world’s leading and most valued generics company. Our purpose is to pioneer access for patients by developing and commercializing novel, affordable approaches that address unmet medical needs.

Medicine 52

Medicine Generic Pharmaceutical Development Sales 52

The Pharma Data

MARCH 15, 2022

The FDA regularly takes steps to help guide industry through the development process for generic drug products, including combination products, such as MDIs, that consist of a drug and a device.

FDA Approval 52

FDA Approval Generic Drugs Production Drugs 52

Pharmaceutical Technology

DECEMBER 22, 2022

The organisation is a non-profit generic pharmaceutical company and has launched its Insulin Initiative, which aims to drive affordability and accessibility for all Americans, regardless of insurance status.

Insulin 130

Insulin Production Development Genetics 130

The Pharma Data

MAY 8, 2021

Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. Our ambition is to be the world’s leading and most valued generics company. About Sandoz. Our purpose is to pioneer access for patients by developing and commercializing novel, affordable approaches that address unmet medical needs.

Clinical Development 52

Clinical Development Medicine Development Containment 52

The Pharma Data

OCTOBER 26, 2021

Sandoz is a global leader in generic pharmaceuticals and biosimilars. Its global portfolio covers all major therapeutic areas with a global market leadership position in biosimilars, generic antibiotics and oncology medicines.

Medicine 52

Medicine Sales Marketing Clinical Trials 52

The Pharma Data

MAY 18, 2021

Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. Our ambition is to be the world’s leading and most valued generics company. About Sandoz. Our purpose is to pioneer access for patients by developing and commercializing novel, affordable approaches that address unmet medical needs.

Manufacturing 40

Manufacturing Production Containment Generic Pharmaceutical 40

The Pharma Data

MAY 2, 2021

Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. Our ambition is to be the world’s leading and most valued generics company. About Sandoz. Our purpose is to pioneer access for patients by developing and commercializing novel, affordable approaches that address unmet medical needs.

Clinical Development 40

Clinical Development Medicine Development Production 40